SG10201804945WA - Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof - Google Patents

Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof

Info

Publication number
SG10201804945WA
SG10201804945WA SG10201804945WA SG10201804945WA SG10201804945WA SG 10201804945W A SG10201804945W A SG 10201804945WA SG 10201804945W A SG10201804945W A SG 10201804945WA SG 10201804945W A SG10201804945W A SG 10201804945WA SG 10201804945W A SG10201804945W A SG 10201804945WA
Authority
SG
Singapore
Prior art keywords
antibody
antigen
binding fragment
medical application
human
Prior art date
Application number
SG10201804945WA
Inventor
Jijun Yuan
Xiangdong Qu
Jufang Lin
Xin Ye
Guoqing Cao
Weikang Tao
Lianshan Zhang
Lei Zhang
Li Yang
Original Assignee
Shanghai hengrui pharmaceutical co ltd
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53370605&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201804945W(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shanghai hengrui pharmaceutical co ltd, Jiangsu Hengrui Medicine Co filed Critical Shanghai hengrui pharmaceutical co ltd
Publication of SG10201804945WA publication Critical patent/SG10201804945WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

PD-1 ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF, AND MEDICAL APPLICATION THEREOF The present invention provides a human PD-1 antibody, an antigen-binding fragment 5 thereof, and medical use thereof, and further provides a chimeric antibody and humanized antibodies comprising a complementarity-determining region (CDR) of the antibody, a pharmaceutical composition comprising the human PD-1 antibody and the antigen-binding fragment thereof, and use of the antibody in preparing medicines for treating diseases or disorders. 10 Figure 1 accompanies the abstract. 15
SG10201804945WA 2013-12-12 2014-11-14 Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof SG10201804945WA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201310681942 2013-12-12

Publications (1)

Publication Number Publication Date
SG10201804945WA true SG10201804945WA (en) 2018-07-30

Family

ID=53370605

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201804945WA SG10201804945WA (en) 2013-12-12 2014-11-14 Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
SG11201604738TA SG11201604738TA (en) 2013-12-12 2014-11-14 Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201604738TA SG11201604738TA (en) 2013-12-12 2014-11-14 Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof

Country Status (35)

Country Link
US (2) US10344090B2 (en)
EP (1) EP3081576B1 (en)
JP (1) JP6502959B2 (en)
KR (1) KR102256152B1 (en)
CN (1) CN105026428B (en)
AU (1) AU2014361473B2 (en)
BR (1) BR112016013338B1 (en)
CA (1) CA2932966C (en)
CL (1) CL2016001460A1 (en)
CR (1) CR20160319A (en)
CY (1) CY1122245T1 (en)
DK (1) DK3081576T3 (en)
DO (1) DOP2016000133A (en)
EA (1) EA035037B1 (en)
EC (1) ECSP16060104A (en)
ES (1) ES2746805T3 (en)
HK (1) HK1213910A1 (en)
HR (1) HRP20191678T1 (en)
HU (1) HUE046249T2 (en)
IL (1) IL246137B (en)
LT (1) LT3081576T (en)
ME (1) ME03527B (en)
MX (1) MX370449B (en)
MY (1) MY184154A (en)
PE (1) PE20160953A1 (en)
PH (1) PH12016501120B1 (en)
PL (1) PL3081576T3 (en)
PT (1) PT3081576T (en)
RS (1) RS59480B1 (en)
SG (2) SG10201804945WA (en)
SI (1) SI3081576T1 (en)
TW (1) TWI654201B (en)
UA (1) UA119659C2 (en)
WO (1) WO2015085847A1 (en)
ZA (1) ZA201604660B (en)

Families Citing this family (361)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2378407T3 (en) 2006-09-01 2012-04-12 Therapeutic Human Polyclonals, Inc. Increased expression of human or humanized immunoglobulin in non-human transgenic animals
SG10201708690SA (en) 2008-12-09 2017-12-28 Genentech Inc Anti-pd-l1 antibodies and their use to enhance t-cell function
US9416132B2 (en) 2011-07-21 2016-08-16 Tolero Pharmaceuticals, Inc. Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors
EP3757130A1 (en) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
SI3081576T1 (en) 2013-12-12 2019-12-31 Shanghai Hengrui Pharmaceutical Co., Ltd., Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
JOP20200094A1 (en) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc Antibody molecules to pd-1 and uses thereof
JOP20200096A1 (en) 2014-01-31 2017-06-16 Children’S Medical Center Corp Antibody molecules to tim-3 and uses thereof
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US9394365B1 (en) 2014-03-12 2016-07-19 Yeda Research And Development Co., Ltd Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
RU2690670C2 (en) 2014-03-12 2019-06-05 Ида Рисерч Энд Дивелопмент Ко., Лтд Reduced levels or activity of systemic regulatory t cells for treating disease or cns injury
EP3659621A1 (en) 2014-09-13 2020-06-03 Novartis AG Combination therapies for cancer
SG11201701340RA (en) 2014-09-16 2017-03-30 Innate Pharma Neutralization of inhibitory pathways in lymphocytes
EP3736294A3 (en) 2014-10-10 2021-02-17 Innate Pharma Cd73 blockade
US11933786B2 (en) 2015-03-30 2024-03-19 Stcube, Inc. Antibodies specific to glycosylated PD-L1 and methods of use thereof
LT3303394T (en) 2015-05-29 2020-10-12 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
BR112018000768A2 (en) 2015-07-13 2018-09-25 Cytomx Therapeutics Inc anti-pd-1 antibodies, activatable anti-pd-1 antibodies and methods of use
KR20180093127A (en) 2015-07-30 2018-08-20 마크로제닉스, 인크. PD-1-Binding Molecules and Methods of Use Thereof
WO2017020291A1 (en) * 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
WO2017024465A1 (en) * 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
JP6868862B2 (en) * 2015-08-31 2021-05-12 国立研究開発法人産業技術総合研究所 Mesoporous silica particles
PE20181322A1 (en) 2015-09-01 2018-08-14 Agenus Inc ANTI-PD1 ANTIBODY AND ITS METHODS OF USE
JP6921062B2 (en) * 2015-09-28 2021-08-18 スーヂョウ サンケイディア バイオファーマスーティカルズ カンパニー リミテッド Stable anti-PD-1 antibody pharmaceutical preparation and its application in pharmaceuticals
WO2017058859A1 (en) 2015-09-29 2017-04-06 Celgene Corporation Pd-1 binding proteins and methods of use thereof
BR112018006547A2 (en) 2015-09-29 2018-12-11 Asia Biotech Pte. Ltd pd-1 antibodies and uses thereof
KR102146319B1 (en) 2015-10-02 2020-08-25 에프. 호프만-라 로슈 아게 Bispecific antibodies specific for PD1 and TIM3
RU2750675C1 (en) 2015-10-02 2021-07-01 Симфоген А/С Antibodies to pd-1 and compositions
US11130817B2 (en) 2015-10-12 2021-09-28 Innate Pharma CD73 blocking agents
SG10202006332PA (en) * 2015-10-29 2020-08-28 Hoffmann La Roche Transgenic rabbit with common light chain
RS63125B1 (en) 2015-11-03 2022-05-31 Janssen Biotech Inc Antibodies specifically binding pd-1 and their uses
CN107614529B (en) * 2015-11-17 2019-11-12 苏州盛迪亚生物医药有限公司 PD-L1 antibody, its antigen-binding fragment and its medical usage
AU2016355570B2 (en) 2015-11-18 2020-01-02 Merck Sharp & Dohme Llc PD1 and/or LAG3 binders
US10858432B2 (en) * 2015-12-02 2020-12-08 Stcube, Inc. Antibodies specific to glycosylated PD-1 and methods of use thereof
US10954301B2 (en) 2015-12-14 2021-03-23 Macrogenics, Inc. Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
US10392442B2 (en) 2015-12-17 2019-08-27 Bristol-Myers Squibb Company Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment
SI3405495T1 (en) 2016-01-21 2021-08-31 Innate Pharma Neutralization of inhibitory pathways in lymphocytes
MA44236A (en) 2016-02-17 2018-12-26 Novartis Ag ANTI-TGFBETA ANTIBODY 2
JP7270379B2 (en) 2016-03-08 2023-05-10 イナート・ファルマ・ソシエテ・アノニム Siglec neutralizing antibody
US20200232974A1 (en) 2016-03-30 2020-07-23 Centre Léon-Bérard Lymphocytes expressing cd73 in cancerous patient dictates therapy
PL3458478T3 (en) * 2016-05-18 2021-06-28 Boehringer Ingelheim International Gmbh Anti pd-1 and anti-lag3 antibodies for cancer treatment
CN105968200B (en) 2016-05-20 2019-03-15 瑞阳(苏州)生物科技有限公司 Anti human PD-L 1 Humanized monoclonal antibodies and its application
CN106008714B (en) 2016-05-24 2019-03-15 瑞阳(苏州)生物科技有限公司 Anti-human PD-1 Humanized monoclonal antibodies and its application
KR102543118B1 (en) 2016-05-27 2023-06-14 아게누스 인코포레이티드 Anti-tim-3 antibodies and methods of use thereof
BR112018074619A2 (en) 2016-06-02 2019-03-06 Bristol Myers Squibb Co use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in cancer treatment
KR20190015377A (en) 2016-06-02 2019-02-13 브리스톨-마이어스 스큅 컴퍼니 PD-1 blockade using nobilvir in refractory Hodgkin's lymphoma
WO2017210631A1 (en) 2016-06-03 2017-12-07 Bristol-Myers Squibb Company Anti-pd-1 antibody for use in a method of treatment of recurrent small cell lung cancer
KR102515509B1 (en) 2016-06-03 2023-03-28 브리스톨-마이어스 스큅 컴퍼니 Use of Anti-PD-1 Antibodies in the Treatment of Patients with Colorectal Cancer
US20200325226A1 (en) 2016-06-03 2020-10-15 Bristol-Myers Squibb Company Anti-pd-1 antibody for use in a method of treating a tumor
WO2017218533A1 (en) 2016-06-13 2017-12-21 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
CN109475603B (en) 2016-06-20 2023-06-13 科马布有限公司 anti-PD-L1 antibodies
EP3487883B1 (en) 2016-07-20 2023-01-04 Stcube, Inc. Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated pd-l1
CN106977602B (en) * 2016-08-23 2018-09-25 中山康方生物医药有限公司 A kind of anti-PD1 monoclonal antibodies, its medical composition and its use
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
CN106967172B (en) 2016-08-23 2019-01-08 康方药业有限公司 The anti-PD-1 bifunctional antibody of anti-CTLA 4-, its medical composition and its use
KR102266788B1 (en) 2016-09-14 2021-06-22 베이징 한미 파마슈티컬 컴퍼니 리미티드 Antibodies specifically binding to PD-1 and functional fragments thereof
JP2019534859A (en) 2016-09-19 2019-12-05 セルジーン コーポレイション Method for treating vitiligo using PD-1 binding protein
SG11201901950TA (en) 2016-09-19 2019-04-29 Celgene Corp Methods of treating immune disorders using pd-1 binding proteins
TWI764943B (en) * 2016-10-10 2022-05-21 大陸商蘇州盛迪亞生物醫藥有限公司 Combination use of anti-pd-1 antibody and vegfr inhibitor in the preparation of a medicament for the treatment of cancer
US10844119B2 (en) 2016-10-11 2020-11-24 Agenus Inc. Anti-LAG-3 antibodies and methods of use thereof
CN108778332B (en) * 2016-10-21 2019-10-18 苏州盛迪亚生物医药有限公司 PD-1 antibody is combined with IDO inhibitor is preparing the purposes in anti-tumor drug
CN110099925A (en) 2016-10-28 2019-08-06 百时美施贵宝公司 Use the method for anti-PD-1 Antybody therapy urothelial cancer
BR112019008859A2 (en) * 2016-11-01 2019-07-09 Anaptysbio Inc antibodies directed against programmed death 1 (pd-1)
MD3535298T2 (en) * 2016-11-02 2022-01-31 Jounce Therapeutics Inc Antibodies to pd-1 and uses thereof
MX2019004775A (en) 2016-11-03 2019-08-05 Squibb Bristol Myers Co Activatable anti-ctla-4 antibodies and uses thereof.
WO2018089293A2 (en) * 2016-11-08 2018-05-17 Qilu Puget Sound Biotherapeutics Corporation Anti-pd1 and anti-ctla4 antibodies
US11279694B2 (en) 2016-11-18 2022-03-22 Sumitomo Dainippon Pharma Oncology, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
CN108079292A (en) * 2016-11-23 2018-05-29 苏州盛迪亚生物医药有限公司 A kind of purposes of anti-PD-1 antibody in the drug for preparing treatment liver cancer
IL307242A (en) 2016-12-07 2023-11-01 Agenus Inc Anti-ctla-4 antibodies and methods of use thereof
CN110300599A (en) 2016-12-07 2019-10-01 艾吉纳斯公司 Antibody and its application method
EA039433B1 (en) 2017-01-05 2022-01-27 Нетрис Фарма Combined treatment with netrin-1 interfering drugs and immune checkpoint inhibitors drugs
SG11201906192SA (en) 2017-01-09 2019-08-27 Tesaro Inc Methods of treating cancer with anti-pd-1 antibodies
ES2902670T3 (en) * 2017-01-13 2022-03-29 Taizhou Hanzhong Biopharmaceutics Inc Monoclonal antibody against PD-1 and applications thereof
MA47265A (en) 2017-01-13 2019-11-20 Agenus Inc T-LYMPHOCYTE RECEPTORS THAT BIND TO NY-ESO-1 AND METHODS OF USING SUCH
EP3570870A1 (en) 2017-01-20 2019-11-27 Novartis AG Combination therapy for the treatment of cancer
CN117586401A (en) * 2017-01-20 2024-02-23 大有华夏生物医药集团有限公司 anti-PD-1 antibodies and uses thereof
CN108341871A (en) * 2017-01-24 2018-07-31 三生国健药业（上海）股份有限公司 Anti- PD-1 monoclonal antibodies and its preparation method and application
CN108387731A (en) * 2017-02-03 2018-08-10 武汉三鹰生物技术有限公司 A kind of enzyme linked immunosorbent detection and preparation method for people's PD1 albumen
WO2018141959A1 (en) 2017-02-06 2018-08-09 Innate Pharma Immunomodulatory antibody drug conjugates binding to a human mica polypeptide
AU2018217963B2 (en) 2017-02-10 2020-11-19 Novartis Ag 1-(4-amino-5-bromo-6-(1 H-pyrazol-1-yl)pyrimidin-2-yl)-1 H-pyrazol-4-ol and use thereof in the treatment of cancer
TWI674261B (en) 2017-02-17 2019-10-11 美商英能腫瘤免疫股份有限公司 Nlrp3 modulators
TW201842921A (en) 2017-02-28 2018-12-16 法商賽諾菲公司 Therapeutic rna
MX2019010848A (en) 2017-03-16 2019-10-30 Innate Pharma Compositions and methods for treating cancer.
EP3601355A1 (en) 2017-03-31 2020-02-05 Bristol-Myers Squibb Company Methods of treating tumor
CA3053357A1 (en) 2017-04-03 2018-10-11 F. Hoffmann-La Roche Ag Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
CA3185303A1 (en) 2017-04-05 2018-10-11 Symphogen A/S Combination therapies targeting pd-a, tim-3, and lag-3
KR102408873B1 (en) 2017-04-05 2022-06-15 에프. 호프만-라 로슈 아게 Bispecific antibodies specifically binding to pd1 and lag3
TWI788340B (en) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 Anti-icos agonist antibodies and uses thereof
JP7297672B2 (en) 2017-04-13 2023-06-26 アジェナス インコーポレイテッド ANTI-CD137 ANTIBODY AND METHODS OF USE THEREOF
CN106939049B (en) 2017-04-20 2019-10-01 苏州思坦维生物技术股份有限公司 The monoclonal antibody and the preparation method and application thereof of antagonism inhibition people PD-1 antigen and its ligand binding
AR111651A1 (en) 2017-04-28 2019-08-07 Novartis Ag CONJUGATES OF ANTIBODIES THAT INCLUDE TOLL TYPE RECEIVER AGONISTS AND COMBINATION THERAPIES
HUE062927T2 (en) 2017-05-01 2023-12-28 Agenus Inc Anti-tigit antibodies and methods of use thereof
AR111760A1 (en) 2017-05-19 2019-08-14 Novartis Ag COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF SOLID TUMORS THROUGH INTRATUMORAL ADMINISTRATION
KR20200010500A (en) 2017-05-30 2020-01-30 브리스톨-마이어스 스큅 컴퍼니 A composition comprising a combination of anti-LAG-3 antibodies, PD-1 pathway inhibitors, and immunotherapy agents
BR112019020610A2 (en) 2017-05-30 2020-04-22 Bristol-Myers Squibb Company treatment of positive tumors for lag-3
BR112019021847A2 (en) 2017-05-30 2020-06-02 Bristol-Myers Squibb Company COMPOSITIONS UNDERSTANDING AN ANTI-LAG-3 ANTIBODY OR ANTI-LAG-3 ANTIBODY AND AN ANTI-PD-1 OR ANTI-PD-L1 ANTIBODY
JOP20190279A1 (en) 2017-05-31 2019-11-28 Novartis Ag Crystalline forms of 5-bromo-2,6-di(1 h-pyrazol-1-yl)pyrimidin-4-amine and new salts
EP3630840A1 (en) 2017-06-01 2020-04-08 Bristol-Myers Squibb Company Methods of treating a tumor using an anti-pd-1 antibody
BR112019025574A2 (en) 2017-06-05 2020-06-23 Janssen Biotech, Inc. ANTIBODIES THAT SPECIFICALLY CONNECT TO PD-1 AND METHODS OF USE
WO2018223923A1 (en) * 2017-06-05 2018-12-13 江苏恒瑞医药股份有限公司 Use of pd-1 antibody combined with vegf ligand or vegf receptor inhibitor in preparing drug for treating tumor
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
EP3641812A1 (en) 2017-06-22 2020-04-29 Novartis AG Antibody molecules to cd73 and uses thereof
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag Antibody molecules to cd73 and uses thereof
WO2018234879A1 (en) 2017-06-22 2018-12-27 Novartis Ag Il-1beta binding antibodies for use in treating cancer
WO2018235056A1 (en) 2017-06-22 2018-12-27 Novartis Ag Il-1beta binding antibodies for use in treating cancer
CN111050791A (en) 2017-06-27 2020-04-21 诺华股份有限公司 Dosing regimens for anti-TIM-3 antibodies and uses thereof
US11623954B2 (en) 2017-07-10 2023-04-11 Innate Pharma Siglec-9-neutralizing antibodies
PE20200296A1 (en) 2017-07-14 2020-02-06 Innate Tumor Immunity Inc NLRP3 MODULATORS
CA3070095A1 (en) 2017-07-20 2019-01-24 Novartis Ag Dosage regimens of anti-lag-3 antibodies and uses thereof
EP3658565B1 (en) 2017-07-28 2022-11-09 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
RS63101B1 (en) 2017-08-03 2022-04-29 Amgen Inc Interleukin-21 muteins and methods of treatment
KR20200039796A (en) 2017-08-31 2020-04-16 브리스톨-마이어스 스큅 컴퍼니 Cyclic dinucleotide as an anticancer agent
JP7209697B2 (en) 2017-08-31 2023-01-20 ブリストル－マイヤーズ スクイブ カンパニー Cyclic dinucleotides as anticancer agents
WO2019046500A1 (en) 2017-08-31 2019-03-07 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
EP3679062A1 (en) 2017-09-04 2020-07-15 Agenus Inc. T cell receptors that bind to mixed lineage leukemia (mll)-specific phosphopeptides and methods of use thereof
WO2019055579A1 (en) 2017-09-12 2019-03-21 Tolero Pharmaceuticals, Inc. Treatment regimen for cancers that are insensitive to bcl-2 inhibitors using the mcl-1 inhibitor alvocidib
BR112020006809A2 (en) 2017-10-06 2020-10-06 Innate Pharma antibodies, agent, use, compound, pharmaceutical composition, kits and composition or use
WO2019074887A1 (en) 2017-10-10 2019-04-18 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
WO2019072220A1 (en) * 2017-10-13 2019-04-18 江苏恒瑞医药股份有限公司 Use of pd-1 antibody combined with epigenetic regulator in preparation of drug for treating tumors
EP3694884A1 (en) 2017-10-15 2020-08-19 Bristol-Myers Squibb Company Methods of treating tumor
WO2019079261A1 (en) 2017-10-16 2019-04-25 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
CN111094339B (en) * 2017-10-17 2023-01-24 江苏恒瑞医药股份有限公司 Application of anti-PD-1 antibody and anti-LAG-3 antibody in preparation of medicine for treating tumor
US20210040205A1 (en) 2017-10-25 2021-02-11 Novartis Ag Antibodies targeting cd32b and methods of use thereof
AU2018360790A1 (en) 2017-11-06 2020-06-11 Bristol-Myers Squibb Company Methods of treating a tumor
AU2018359967A1 (en) 2017-11-06 2020-04-23 Genentech, Inc. Diagnostic and therapeutic methods for cancer
CN109793892B (en) * 2017-11-16 2022-07-26 江苏恒瑞医药股份有限公司 Application of anti-PD-1 antibody in preparation of medicine for treating esophageal cancer
CN111655288A (en) 2017-11-16 2020-09-11 诺华股份有限公司 Combination therapy
TW201922793A (en) * 2017-11-16 2019-06-16 大陸商江蘇恆瑞醫藥股份有限公司 Uses of PD-1 antibody combined with VEGFR inhibitor for treating small cell lung cancer
WO2019096233A1 (en) * 2017-11-17 2019-05-23 江苏恒瑞医药股份有限公司 Use of combination of immunotherapeutic agent, nucleoside antimetabolite, and platinum in preparing drug for treating tumor
CN109806393B (en) * 2017-11-17 2022-07-26 江苏恒瑞医药股份有限公司 Application of anti-PD-1 antibody, pemetrexed and platinum drugs in combined treatment of non-small cell lung cancer
CA3083949A1 (en) 2017-11-30 2020-06-06 Novartis Ag Bcma-targeting chimeric antigen receptor, and uses thereof
WO2019114785A1 (en) * 2017-12-14 2019-06-20 江苏恒瑞医药股份有限公司 Use of pd-1 antibody in treating tumor
US20210363253A1 (en) 2017-12-29 2021-11-25 Jiangsu Hengrui Medicine Co., Ltd. Use of combined treatment of pd-1 antibody and apatinib for treating triple negative breast cancer
CN112218651A (en) 2018-01-08 2021-01-12 诺华公司 Immunopotentiating RNA for combination with chimeric antigen receptor therapy
CN110013552B (en) * 2018-01-08 2023-03-10 江苏恒瑞医药股份有限公司 Application of anti-PD-1 antibody, gemcitabine and platinum drug combination in treating malignant biliary tract tumor
EP3737694B1 (en) 2018-01-12 2023-03-01 Amgen Inc. Anti-pd-1 antibodies and methods of treatment
EP3740506A1 (en) 2018-01-16 2020-11-25 Bristol-Myers Squibb Company Methods of treating cancer with antibodies against tim3
CN111629731A (en) 2018-01-22 2020-09-04 百时美施贵宝公司 Compositions and methods for treating cancer
CA3096287A1 (en) 2018-01-22 2019-07-25 Pascal Biosciences Inc. Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells
WO2019152660A1 (en) 2018-01-31 2019-08-08 Novartis Ag Combination therapy using a chimeric antigen receptor
WO2019151771A1 (en) * 2018-02-02 2019-08-08 주식회사 뉴라클제네틱스 Pd-1 variant having improved binding to pd-l1
US20200399383A1 (en) 2018-02-13 2020-12-24 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
US10519187B2 (en) 2018-02-13 2019-12-31 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
US11945834B2 (en) 2018-03-08 2024-04-02 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
GB201803745D0 (en) * 2018-03-08 2018-04-25 Ultrahuman Eight Ltd PD1 binding agents
GB201803746D0 (en) * 2018-03-08 2018-04-25 Ultrahuman Eight Ltd PD1 binding agents
CN110272491B (en) * 2018-03-13 2023-01-24 江苏恒瑞医药股份有限公司 Purification process of anti-PD-1 antibody
AU2019236865A1 (en) 2018-03-23 2020-10-01 Bristol-Myers Squibb Company Antibodies against MICA and/or MICB and uses thereof
CN111971306A (en) 2018-03-30 2020-11-20 百时美施贵宝公司 Method for treating tumors
KR20200140315A (en) 2018-04-04 2020-12-15 브리스톨-마이어스 스큅 컴퍼니 Anti-CD27 antibodies and uses thereof
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
US20210267964A1 (en) 2018-04-25 2021-09-02 Innate Tumor Immunity, Inc. Nlrp3 modulators
JP2021522239A (en) 2018-04-26 2021-08-30 アジェナス インコーポレイテッド Heat shock protein-binding peptide composition and how to use it
EP3788147A1 (en) 2018-05-04 2021-03-10 Tollys Tlr3 ligands that activate both epithelial and myeloid cells
IL278400B2 (en) 2018-05-07 2024-03-01 Genmab As Combination of an anti pd-1 antibody and anti tissue factor (tf) antibody drug conjugate for use in the treatment of cancer
EP3794039A4 (en) 2018-05-17 2022-05-04 Nanjing Leads Biolabs Co., Ltd. Antibody binding pd-1 and use thereof
CN110507820A (en) * 2018-05-21 2019-11-29 江苏恒瑞医药股份有限公司 A kind of purposes of the antibody combined radiotherapy of anti-PD-1 in the drug of preparation treatment tumor patient
TWI806870B (en) * 2018-05-23 2023-07-01 中國大陸商大有華夏生物醫藥集團有限公司 Anti-pd-1 antibodies and uses thereof
TW202015726A (en) 2018-05-30 2020-05-01 瑞士商諾華公司 Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
TW202017569A (en) 2018-05-31 2020-05-16 美商佩樂敦治療公司 Compositions and methods for inhibiting cd73
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
EP3802611A2 (en) 2018-06-01 2021-04-14 Novartis AG Binding molecules against bcma and uses thereof
CN108636356A (en) * 2018-06-05 2018-10-12 吉林农业大学 A kind of cornstalk biological charcoal and restorative procedure that can repair nitrogen phosphorus pollution of area source
CA3099893A1 (en) 2018-06-18 2019-12-26 Innate Pharma Compositions and methods for treating cancer
US20200030443A1 (en) 2018-06-23 2020-01-30 Genentech, Inc. Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
AR116109A1 (en) 2018-07-10 2021-03-31 Novartis Ag DERIVATIVES OF 3- (5-AMINO-1-OXOISOINDOLIN-2-IL) PIPERIDINE-2,6-DIONA AND USES OF THE SAME
SG11202011872QA (en) 2018-07-10 2021-01-28 Novartis Ag 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases
AU2019305857A1 (en) 2018-07-18 2021-02-18 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Drug combination of quinoline derivative and antibody
KR20210034622A (en) 2018-07-18 2021-03-30 제넨테크, 인크. Lung cancer treatment method using PD-1 axis binding antagonist, anti-metabolite, and platinum agent
US20210261665A1 (en) * 2018-07-19 2021-08-26 Tayu Huaxia Biotech Medical Group Co., Ltd. Anti-pd-1 antibodies, dosages and uses thereof
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
AU2019309849A1 (en) 2018-07-26 2021-03-18 Bristol-Myers Squibb Company LAG-3 combination therapy for the treatment of cancer
CN110790839B (en) * 2018-08-03 2023-05-12 江苏恒瑞医药股份有限公司 anti-PD-1 antibody, antigen binding fragment thereof and medical application thereof
US20210317118A1 (en) 2018-08-16 2021-10-14 Innate Tumor Immunity, Inc. Nlrp3 modulators
ES2930171T3 (en) 2018-08-16 2022-12-07 Innate Tumor Immunity Inc Imidazo[4,5-C]quinoline-derived NLRP3 modulators
SG11202101486RA (en) 2018-08-16 2021-03-30 Innate Tumor Immunity Inc Substitued 4-amino-1h-imidazo[4,5-c]quinoline compounds and improved methods for their preparation
WO2020038355A1 (en) * 2018-08-20 2020-02-27 江苏恒瑞医药股份有限公司 Use of tim-3 antibody in preparation of medicines for treating tumors
WO2020044252A1 (en) 2018-08-31 2020-03-05 Novartis Ag Dosage regimes for anti-m-csf antibodies and uses thereof
TW202024023A (en) 2018-09-03 2020-07-01 瑞士商赫孚孟拉羅股份公司 Therapeutic compounds and methods of use
WO2020049534A1 (en) 2018-09-07 2020-03-12 Novartis Ag Sting agonist and combination therapy thereof for the treatment of cancer
US20210395392A1 (en) 2018-10-09 2021-12-23 Bristol-Myers Squibb Company Anti-mertk antibodies for treating cancer
JP2022504905A (en) 2018-10-16 2022-01-13 ノバルティス アーゲー Tumor mutation loading alone or in combination with immune markers as a biomarker to predict response to targeted therapy
US20210338813A1 (en) 2018-10-19 2021-11-04 Bristol-Myers Squibb Company Combination Therapy for Melanoma
JP2022505647A (en) 2018-10-23 2022-01-14 ブリストル－マイヤーズ スクイブ カンパニー How to treat a tumor
WO2020089811A1 (en) 2018-10-31 2020-05-07 Novartis Ag Dc-sign antibody drug conjugates
CN117298270A (en) 2018-11-06 2023-12-29 江苏恒瑞医药股份有限公司 Application of anti-PD-1 antibody and famotidine in preparing medicament for treating tumor
JP2022509942A (en) 2018-11-16 2022-01-25 ブリストル－マイヤーズ スクイブ カンパニー Anti-NKG2A antibody and its use
EP3891508A1 (en) 2018-12-04 2021-10-13 Bristol-Myers Squibb Company Methods of analysis using in-sample calibration curve by multiple isotopologue reaction monitoring
US11034710B2 (en) 2018-12-04 2021-06-15 Sumitomo Dainippon Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
EP3666905A1 (en) 2018-12-11 2020-06-17 Sanofi E. coli positive for pks island as marker of positive response to anti-pd1 therapy in colorectal cancer
EP3894401A2 (en) 2018-12-11 2021-10-20 Theravance Biopharma R&D IP, LLC Naphthyridine and quinoline derivatives useful as alk5 inhibitors
MX2021007392A (en) 2018-12-20 2021-08-24 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives.
WO2020128620A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1beta binding antibodies
KR20210107730A (en) 2018-12-21 2021-09-01 노파르티스 아게 Use of IL-1 beta antibodies in the treatment or prevention of myelodysplastic syndrome
WO2020128637A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1 binding antibodies in the treatment of a msi-h cancer
WO2020128613A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1beta binding antibodies
CN111349162A (en) * 2018-12-21 2020-06-30 神州细胞工程有限公司 Humanized anti-PD-1 antibodies and uses thereof
JP7450622B2 (en) 2018-12-21 2024-03-15 ヴァレリオ・セラピューティクス Novel conjugated nucleic acid molecules and their uses
JP7340021B2 (en) 2018-12-23 2023-09-06 エフ． ホフマン－ラ ロシュ アーゲー Tumor classification based on predicted tumor mutational burden
CN111423510B (en) 2019-01-10 2024-02-06 迈威(上海)生物科技股份有限公司 Recombinant anti-human PD-1 antibody and application thereof
CN113286787A (en) 2019-01-14 2021-08-20 先天肿瘤免疫公司 NLRP3 modulators
MX2021008434A (en) 2019-01-14 2021-09-23 Genentech Inc Methods of treating cancer with a pd-1 axis binding antagonist and an rna vaccine.
JP2022517111A (en) 2019-01-14 2022-03-04 イネイト・テューマー・イミュニティ・インコーポレイテッド Heterocyclic NLRP3 modulator for use in the treatment of cancer
US20220089571A1 (en) 2019-01-14 2022-03-24 Innate Tumor Immunity, Inc. Nlrp3 modulators
WO2020150115A1 (en) 2019-01-14 2020-07-23 Innate Tumor Immunity, Inc. Nlrp3 modulators
SG11202107396RA (en) 2019-01-21 2021-08-30 Sanofi Sa Therapeutic rna and anti-pd1 antibodies for advanced stage solid tumor cancers
CN112969716B (en) * 2019-02-03 2022-11-22 江苏恒瑞医药股份有限公司 anti-PD-1 antibody, antigen binding fragment thereof and medical application
CA3129031A1 (en) 2019-02-12 2020-08-20 Novartis Ag Pharmaceutical combination comprising tno155 and a pd-1 inhibitor
CA3127502A1 (en) 2019-02-12 2020-08-20 Sumitomo Dainippon Pharma Oncology, Inc. Formulations comprising heterocyclic protein kinase inhibitors
EP3924055B1 (en) 2019-02-15 2024-04-03 Novartis AG Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
MX2021009763A (en) 2019-02-15 2021-09-08 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof.
JP2022525149A (en) 2019-03-20 2022-05-11 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド Treatment of Acute Myeloid Leukemia (AML) with Venetoclax Failure
US11712433B2 (en) 2019-03-22 2023-08-01 Sumitomo Pharma Oncology, Inc. Compositions comprising PKM2 modulators and methods of treatment using the same
CN113677402A (en) 2019-03-28 2021-11-19 百时美施贵宝公司 Method for treating tumors
US20220195046A1 (en) 2019-03-28 2022-06-23 Bristol-Myers Squibb Company Methods of treating tumor
AU2020258480A1 (en) 2019-04-19 2021-10-21 Genentech, Inc. Anti-mertk antibodies and their methods of use
EP3725370A1 (en) 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
KR20220002959A (en) 2019-04-23 2022-01-07 이나뜨 파르마 에스.에이. CD73 blocking antibody
CN113747897B (en) 2019-05-10 2024-04-02 正大天晴药业集团股份有限公司 Quinoline derivatives and antibodies for combined treatment of soft tissue sarcomas
US20230242478A1 (en) 2019-05-13 2023-08-03 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
WO2020231766A1 (en) 2019-05-13 2020-11-19 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
AU2020279289A1 (en) 2019-05-20 2022-01-06 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Quinoline derivative used for combination treatment of small cell lung cancer
EP3973963A4 (en) 2019-05-23 2023-06-14 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Quinoline derivatives for treatment of head and neck cancer
JP2022534889A (en) 2019-05-24 2022-08-04 ファイザー・インコーポレイテッド Combination therapy using CDK inhibitors
US20220233691A1 (en) 2019-05-30 2022-07-28 Bristol-Myers Squibb Company Cell localization signature and combination therapy
EP3976832A1 (en) 2019-05-30 2022-04-06 Bristol-Myers Squibb Company Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
CN114174538A (en) 2019-05-30 2022-03-11 百时美施贵宝公司 Multiple tumor gene signatures suitable for immunooncology therapy
US11529350B2 (en) 2019-07-03 2022-12-20 Sumitomo Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof
EP3998081A4 (en) 2019-07-05 2023-07-12 Ono Pharmaceutical Co., Ltd. Treatment of hematologic cancer with pd-1/cd3 dual specificity protein
WO2021026179A1 (en) 2019-08-06 2021-02-11 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
WO2021025140A1 (en) 2019-08-08 2021-02-11 小野薬品工業株式会社 Dual-specific protein
KR20220053007A (en) 2019-08-30 2022-04-28 아게누스 인코포레이티드 Anti-CD96 antibodies and methods of use thereof
US20220348651A1 (en) 2019-09-18 2022-11-03 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
TW202124446A (en) 2019-09-18 2021-07-01 瑞士商諾華公司 Combination therapies with entpd2 antibodies
US20220348653A1 (en) 2019-09-22 2022-11-03 Bristol-Myers Squibb Company Quantitative Spatial Profiling for LAG-3 Antagonist Therapy
AU2020351751A1 (en) 2019-09-25 2022-04-21 Seagen Inc. Combination anti-CD30 ADC, anti-PD-1 and chemotherapeutic for treatment of hematopoietic cancers
BR112022005655A2 (en) 2019-09-25 2022-09-06 Bristol Myers Squibb Co COMPOSITE BIOMARKER FOR CANCER THERAPY
GB201914747D0 (en) * 2019-10-11 2019-11-27 Ultrahuman Eight Ltd PD1 and vegfr2 dual-binding agents
JP2022553306A (en) 2019-10-21 2022-12-22 ノバルティス アーゲー TIM-3 inhibitors and uses thereof
EP4048281A1 (en) 2019-10-21 2022-08-31 Novartis AG Combination therapies with venetoclax and tim-3 inhibitors
WO2021092044A1 (en) 2019-11-05 2021-05-14 Bristol-Myers Squibb Company M-protein assays and uses thereof
WO2021092221A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
WO2021092220A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
KR20220093349A (en) 2019-11-08 2022-07-05 브리스톨-마이어스 스큅 컴퍼니 LAG-3 antagonist therapy for melanoma
CN114728905A (en) 2019-11-13 2022-07-08 基因泰克公司 Therapeutic compounds and methods of use
EP4058465A1 (en) 2019-11-14 2022-09-21 Cohbar Inc. Cxcr4 antagonist peptides
IL293084A (en) 2019-11-22 2022-07-01 Theravance Biopharma R& D Ip Llc Substituted 1,5-naphthyridines or quinolines as alk5 inhibitors
US20230000864A1 (en) 2019-11-22 2023-01-05 Sumitomo Pharma Oncology, Inc. Solid dose pharmaceutical composition
TW202133887A (en) 2019-12-09 2021-09-16 美商西健公司 Combination therapy with liv1-adc and pd-1 antagonist
CA3158532A1 (en) 2019-12-19 2021-06-24 Susan Wee Combinations of dgk inhibitors and checkpoint antagonists
AU2020406350A1 (en) 2019-12-20 2022-08-11 Novartis Ag Uses of anti-TGF-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
CN113004408B (en) * 2019-12-20 2022-07-01 广东菲鹏制药股份有限公司 Anti-human apoptosis factor-1 monoclonal antibody
KR20220127848A (en) 2020-01-10 2022-09-20 인네이트 튜머 이뮤니티, 인코포레이티드 NLRP3 modulators
US20230058489A1 (en) 2020-01-17 2023-02-23 Novartis Ag Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
WO2021152548A1 (en) 2020-01-30 2021-08-05 Benitah Salvador Aznar Combination therapy for treatment of cancer and cancer metastasis
EP4096708A1 (en) 2020-01-31 2022-12-07 Genentech, Inc. Methods of inducing neoepitope-specific t cells with a pd-1 axis binding antagonist and an rna vaccine
US20230087600A1 (en) 2020-02-06 2023-03-23 Bristol-Myers Squibb Company Il-10 and uses thereof
JP2023516155A (en) 2020-02-28 2023-04-18 ノバルティス アーゲー Triple drug combinations containing dabrafenib, ERK inhibitors and RAF inhibitors or PD-1 inhibitors
AU2021232158A1 (en) 2020-03-06 2022-09-29 Ona Therapeutics, S.L. Anti-CD36 antibodies and their use to treat cancer
MX2022010912A (en) 2020-03-06 2022-11-09 Celgene Quanticel Res Inc Combination of an lsd-1 inhibitor and nivolumab for use in treating sclc or sqnsclc.
TW202202521A (en) 2020-03-23 2022-01-16 美商必治妥美雅史谷比公司 Anti-ccr8 antibodies for treating cancer
CN115443269A (en) 2020-03-31 2022-12-06 施万生物制药研发Ip有限责任公司 Substituted pyrimidines and methods of use
CN115279405A (en) * 2020-04-10 2022-11-01 江苏恒瑞医药股份有限公司 Application of anti-PD-1 antibody in preparation of medicine for treating acro-melanoma
BR112022021105A2 (en) 2020-04-21 2022-11-29 Novartis Ag DOSAGE REGIME TO TREAT A CSF-1R MODULATED DISEASE
CN116323607A (en) 2020-06-10 2023-06-23 施万生物制药研发Ip有限责任公司 Naphthyridine derivatives as ALK5 inhibitors
TW202214857A (en) 2020-06-19 2022-04-16 法商昂席歐公司 New conjugated nucleic acid molecules and their uses
JP2023531676A (en) 2020-06-23 2023-07-25 ノバルティス アーゲー Dosing Regimens Containing 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione Derivatives
WO2022003568A1 (en) 2020-06-30 2022-01-06 Dcprime B.V. Use of leukemia-derived cells in ovarian cancer vaccines
IL298993A (en) 2020-07-07 2023-02-01 BioNTech SE Therapeutic rna for hpv-positive cancer
WO2022009157A1 (en) 2020-07-10 2022-01-13 Novartis Ag Lhc165 and spartalizumab combinations for treating solid tumors
US11787775B2 (en) 2020-07-24 2023-10-17 Genentech, Inc. Therapeutic compounds and methods of use
CA3189452A1 (en) 2020-07-31 2022-02-03 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-pd-1 antibody pharmaceutical composition and use thereof
CN116134027A (en) 2020-08-03 2023-05-16 诺华股份有限公司 Heteroaryl-substituted 3- (1-oxo-isoindolin-2-yl) piperidine-2, 6-dione derivatives and uses thereof
CN111705038B (en) * 2020-08-24 2020-11-03 江苏集萃药康生物科技有限公司 Construction method and application of cell strain capable of stably expressing human PDL1/CD73 protein
IL300813A (en) 2020-08-28 2023-04-01 Bristol Myers Squibb Co Lag-3 antagonist therapy for hepatocellular carcinoma
MX2023002326A (en) 2020-08-31 2023-03-21 Bristol Myers Squibb Co Cell localization signature and immunotherapy.
EP4204021A1 (en) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Method of treating psma-expressing cancers
WO2022043558A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
CA3189987A1 (en) 2020-09-02 2022-03-10 Pharmabcine Inc. Combination therapy of a pd-1 antagonist and an antagonist for vegfr-2 for treating patients with cancer
AR123585A1 (en) 2020-09-24 2022-12-21 Merck Sharp & Dohme STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND HYALURONIDASE VARIANTS AND FRAGMENTS THEREOF AND METHODS OF USE THEREOF
CN112285352A (en) * 2020-10-02 2021-01-29 朱吉安 Method for measuring biological activity of anti-PD-1 monoclonal antibody
WO2022076318A1 (en) 2020-10-05 2022-04-14 Bristol-Myers Squibb Company Methods for concentrating proteins
WO2022076596A1 (en) 2020-10-06 2022-04-14 Codiak Biosciences, Inc. Extracellular vesicle-aso constructs targeting stat6
AR123855A1 (en) 2020-10-20 2023-01-18 Genentech Inc PEG-CONJUGATED ANTI-MERTK ANTIBODIES AND METHODS OF USE
CA3196496A1 (en) 2020-10-23 2022-04-28 Laurence David TOMS Lag-3 antagonist therapy for lung cancer
WO2022093981A1 (en) 2020-10-28 2022-05-05 Genentech, Inc. Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
JP2023549678A (en) 2020-10-28 2023-11-29 イケナ オンコロジー， インコーポレイテッド Combination of AHR inhibitors with PDx inhibitors or doxorubicin
AU2021374594A1 (en) 2020-11-04 2023-06-01 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
CA3196076A1 (en) 2020-11-04 2022-05-12 Chi-Chung Li Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
CA3196539A1 (en) 2020-11-04 2022-05-12 Chi-Chung Li Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
WO2022097060A1 (en) 2020-11-06 2022-05-12 Novartis Ag Cd19 binding molecules and uses thereof
KR20230110274A (en) 2020-11-17 2023-07-21 씨젠 인크. Methods of treating cancer with a combination of tucatinib and an anti-PD-1/anti-PD-L1 antibody
EP4255481A1 (en) 2020-12-02 2023-10-11 Genentech, Inc. Methods and compositions for neoadjuvant and adjuvant urothelial carcinoma therapy
WO2022118197A1 (en) 2020-12-02 2022-06-09 Pfizer Inc. Time to resolution of axitinib-related adverse events
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
TW202237119A (en) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Alk-5 inhibitors and uses thereof
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
TW202245808A (en) 2020-12-21 2022-12-01 德商拜恩迪克公司 Therapeutic rna for treating cancer
EP4267172A1 (en) 2020-12-28 2023-11-01 Bristol-Myers Squibb Company Subcutaneous administration of pd1/pd-l1 antibodies
WO2022146947A1 (en) 2020-12-28 2022-07-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
JP2024506249A (en) 2021-01-22 2024-02-13 メンドゥス・ベスローテン・フェンノートシャップ Methods of tumor vaccination
WO2022162569A1 (en) 2021-01-29 2022-08-04 Novartis Ag Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
AU2022218137A1 (en) 2021-02-03 2023-08-24 Mozart Therapeutics, Inc. Binding agents and methods of using the same
WO2022169921A1 (en) 2021-02-04 2022-08-11 Bristol-Myers Squibb Company Benzofuran compounds as sting agonists
JP2024510989A (en) 2021-03-12 2024-03-12 メンドゥス・ベスローテン・フェンノートシャップ Vaccination methods and use of CD47 blockers
WO2022195551A1 (en) 2021-03-18 2022-09-22 Novartis Ag Biomarkers for cancer and methods of use thereof
TW202304506A (en) 2021-03-25 2023-02-01 日商安斯泰來製藥公司 Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
AU2022246593A1 (en) 2021-03-29 2023-10-12 Juno Therapeutics, Inc. Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy
EP4314068A1 (en) 2021-04-02 2024-02-07 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
TW202304979A (en) 2021-04-07 2023-02-01 瑞士商諾華公司 USES OF ANTI-TGFβ ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
JP2024516371A (en) 2021-04-13 2024-04-15 ヌバレント， インク． Amino-Substituted Heterocycles for Treating Cancers with EGFR Mutations - Patent application
WO2022232503A1 (en) 2021-04-30 2022-11-03 Genentech, Inc. Therapeutic and diagnostic methods and compositions for cancer
KR20240005691A (en) 2021-04-30 2024-01-12 에프. 호프만-라 로슈 아게 Dosage for combination therapy with anti-CD20/anti-CD3 bispecific antibody and anti-CD79B antibody drug conjugate
AR125874A1 (en) 2021-05-18 2023-08-23 Novartis Ag COMBINATION THERAPIES
AU2022281461A1 (en) 2021-05-25 2024-01-04 Edelweiss Immune Inc C-x-c motif chemokine receptor 6 (cxcr6) binding molecules, and methods of using the same
WO2022251359A1 (en) 2021-05-26 2022-12-01 Theravance Biopharma R&D Ip, Llc Bicyclic inhibitors of alk5 and methods of use
TW202313679A (en) 2021-06-03 2023-04-01 美商欣爍克斯公司 Head and neck cancer combination therapy comprising an il-2 conjugate and a pd-1 antagonist
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
TW202309078A (en) 2021-07-02 2023-03-01 美商建南德克公司 Methods and compositions for treating cancer
AU2022312698A1 (en) 2021-07-13 2024-01-25 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
WO2023010094A2 (en) 2021-07-28 2023-02-02 Genentech, Inc. Methods and compositions for treating cancer
CN117715936A (en) 2021-07-28 2024-03-15 豪夫迈·罗氏有限公司 Methods and compositions for treating cancer
AU2022320051A1 (en) 2021-07-30 2024-01-25 ONA Therapeutics S.L. Anti-cd36 antibodies and their use to treat cancer
WO2023056403A1 (en) 2021-09-30 2023-04-06 Genentech, Inc. Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
WO2023051926A1 (en) 2021-09-30 2023-04-06 BioNTech SE Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
TW202327595A (en) 2021-10-05 2023-07-16 美商輝瑞大藥廠 Combinations of azalactam compounds for the treatment of cancer
WO2023057534A1 (en) 2021-10-06 2023-04-13 Genmab A/S Multispecific binding agents against pd-l1 and cd137 in combination
TW202333802A (en) 2021-10-11 2023-09-01 德商拜恩迪克公司 Therapeutic rna for lung cancer
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
CA3224890A1 (en) 2021-10-29 2023-05-04 Bristol-Myers Squibb Company Lag-3 antagonist therapy for hematological cancer
WO2023079428A1 (en) 2021-11-03 2023-05-11 Pfizer Inc. Combination therapies using tlr7/8 agonist
WO2023080900A1 (en) 2021-11-05 2023-05-11 Genentech, Inc. Methods and compositions for classifying and treating kidney cancer
WO2023083439A1 (en) 2021-11-09 2023-05-19 BioNTech SE Tlr7 agonist and combinations for cancer treatment
AU2022384793A1 (en) 2021-11-12 2024-04-11 Advanced Accelerator Applications Combination therapy for treating lung cancer
TW202340212A (en) 2021-11-24 2023-10-16 美商建南德克公司 Therapeutic compounds and methods of use
TW202332429A (en) 2021-11-24 2023-08-16 美商建南德克公司 Therapeutic compounds and methods of use
WO2023111203A1 (en) 2021-12-16 2023-06-22 Onxeo New conjugated nucleic acid molecules and their uses
WO2023122573A1 (en) 2021-12-20 2023-06-29 Synthorx, Inc. Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
WO2023147371A1 (en) 2022-01-26 2023-08-03 Bristol-Myers Squibb Company Combination therapy for hepatocellular carcinoma
WO2023164638A1 (en) 2022-02-25 2023-08-31 Bristol-Myers Squibb Company Combination therapy for colorectal carcinoma
WO2023168404A1 (en) 2022-03-04 2023-09-07 Bristol-Myers Squibb Company Methods of treating a tumor
WO2023170606A1 (en) 2022-03-08 2023-09-14 Alentis Therapeutics Ag Use of anti-claudin-1 antibodies to increase t cell availability
WO2023178329A1 (en) 2022-03-18 2023-09-21 Bristol-Myers Squibb Company Methods of isolating polypeptides
WO2023191816A1 (en) 2022-04-01 2023-10-05 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2023196987A1 (en) 2022-04-07 2023-10-12 Bristol-Myers Squibb Company Methods of treating tumor
WO2023196964A1 (en) 2022-04-08 2023-10-12 Bristol-Myers Squibb Company Machine learning identification, classification, and quantification of tertiary lymphoid structures
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
WO2023219613A1 (en) 2022-05-11 2023-11-16 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2023218046A1 (en) 2022-05-12 2023-11-16 Genmab A/S Binding agents capable of binding to cd27 in combination therapy
WO2023230554A1 (en) 2022-05-25 2023-11-30 Pfizer Inc. Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer
WO2023235847A1 (en) 2022-06-02 2023-12-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
WO2023240058A2 (en) 2022-06-07 2023-12-14 Genentech, Inc. Prognostic and therapeutic methods for cancer
WO2024015897A1 (en) 2022-07-13 2024-01-18 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2024020432A1 (en) 2022-07-19 2024-01-25 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
EP4310197A1 (en) 2022-07-21 2024-01-24 Fundación para la Investigación Biomédica del Hospital Universitario Puerta de Hierro Majadahonda Method for identifying lung cancer patients for a combination treatment of immuno- and chemotherapy
WO2024023740A1 (en) 2022-07-27 2024-02-01 Astrazeneca Ab Combinations of recombinant virus expressing interleukin-12 with pd-1/pd-l1 inhibitors
WO2024049949A1 (en) 2022-09-01 2024-03-07 Genentech, Inc. Therapeutic and diagnostic methods for bladder cancer
WO2024069009A1 (en) 2022-09-30 2024-04-04 Alentis Therapeutics Ag Treatment of drug-resistant hepatocellular carcinoma
WO2024077095A1 (en) 2022-10-05 2024-04-11 Genentech, Inc. Methods and compositions for classifying and treating bladder cancer
WO2024077166A1 (en) 2022-10-05 2024-04-11 Genentech, Inc. Methods and compositions for classifying and treating lung cancer

Family Cites Families (195)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5159730A (en) 1974-10-24 1976-05-25 Furukawa Electric Co Ltd Sutenresu no nitsukerumetsukiho
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
CN1080311A (en) 1992-06-14 1994-01-05 江苏省盐城市师范专科学校科技部 A kind of smoke-stopping fireproofing material
CA2143491C (en) 1994-03-01 2011-02-22 Yasumasa Ishida A novel peptide related to human programmed cell death and dna encoding it
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
AU740738B2 (en) * 1997-04-07 2001-11-15 Genentech Inc. Humanized antibodies and methods for forming humanized antibodies
PL354286A1 (en) 1999-08-23 2003-12-29 Dana-Farber Cancer Institutedana-Farber Cancer Institute Pd-1, a receptor for b7-4, and uses therefor
GB0029360D0 (en) * 2000-12-01 2001-01-17 Univ Nottingham Humanised antibodies and uses thereof
AR036993A1 (en) 2001-04-02 2004-10-20 Wyeth Corp USE OF AGENTS THAT MODULATE THE INTERACTION BETWEEN PD-1 AND ITS LINKS IN THE SUBMODULATION OF IMMUNOLOGICAL ANSWERS
DK2206517T3 (en) 2002-07-03 2023-11-06 Ono Pharmaceutical Co Immunopotentiating compositions comprising anti-PD-L1 antibodies
CA2508660C (en) 2002-12-23 2013-08-20 Wyeth Antibodies against pd-1 and uses therefor
EP2270051B1 (en) 2003-01-23 2019-05-15 Ono Pharmaceutical Co., Ltd. Antibody specific for human PD-1 and CD3
GB0400440D0 (en) 2004-01-09 2004-02-11 Isis Innovation Receptor modulators
GB0521621D0 (en) 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
DK2161336T4 (en) * 2005-05-09 2017-04-24 Ono Pharmaceutical Co Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies
EP3130350A1 (en) 2005-06-08 2017-02-15 Dana-Farber Cancer Institute, Inc. Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1)pathway
CN105056226A (en) 2006-12-27 2015-11-18 埃默里大学 Compositions and methods for the treatment of infections and tumors
US20100267934A1 (en) 2007-05-31 2010-10-21 Genmab A/S Stable igg4 antibodies
CA2855098C (en) * 2007-06-18 2018-02-27 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
EP2195347A1 (en) 2007-08-17 2010-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating and diagnosing hematologic malignancies
WO2009026472A1 (en) 2007-08-21 2009-02-26 The General Hospital Corporation Methods for inducing tolerance
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme Pd-1 binding proteins
WO2010001617A1 (en) 2008-07-04 2010-01-07 Ono Pharmaceutical Co., Ltd. Use of an efficacy marker for optimizing therapeutic efficacy of an anti-human pd-1 antibody on cancers
DK2350129T3 (en) 2008-08-25 2015-08-31 Amplimmune Inc PREPARATIONS WITH PD-1 ANTAGONISTS AND PROCEDURES FOR USE THEREOF
KR20110074850A (en) 2008-08-25 2011-07-04 앰플리뮨, 인크. Pd-1 antagonists and methods of use thereof
WO2010029435A1 (en) 2008-09-12 2010-03-18 Isis Innovation Limited Pd-1 specific antibodies and uses thereof
CA2736816C (en) 2008-09-12 2018-05-22 Isis Innovation Limited Pd-1 specific antibodies and uses thereof
EP3530672B1 (en) 2008-09-26 2024-05-01 Dana-Farber Cancer Institute, Inc. Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses thereof
KR20190064664A (en) 2008-10-02 2019-06-10 압테보 리서치 앤드 디벨롭먼트 엘엘씨 CD86 Antagonist Multi-Target Binding Proteins
KR101050829B1 (en) 2008-10-02 2011-07-20 서울대학교산학협력단 Anticancer agents comprising an anti-PD-1 antibody or an anti-PD-L1 antibody
DK2370593T3 (en) 2008-11-28 2016-07-04 Univ Emory A method for determining the effect of PD-1 Antagonists
WO2010063785A2 (en) 2008-12-03 2010-06-10 Genmab A/S Antibody variants having modifications in the constant region
JP5714505B2 (en) * 2008-12-22 2015-05-07 ノヴォ ノルディスク アー／エス Antibodies against tissue factor pathway inhibitor
ES2629337T3 (en) 2009-02-09 2017-08-08 Inserm - Institut National De La Santé Et De La Recherche Médicale Antibodies against PD-1 and antibodies against PD-L1 and uses thereof
WO2010102278A1 (en) 2009-03-06 2010-09-10 President And Fellows Of Harvard College Methods and compositions for the generation and maintenance of regulatory t cells
WO2010106051A1 (en) 2009-03-17 2010-09-23 Universite De La Mediterranee Btla antibodies and uses thereof
EP3375791A1 (en) 2009-09-30 2018-09-19 Memorial Sloan Kettering Cancer Center Combination immunotherapy for the treatment of cancer
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
WO2011100841A1 (en) 2010-02-16 2011-08-25 Valorisation-Recherche, Limited Partnership Pd-1 modulation and uses thereof for modulating hiv replication
WO2011110604A1 (en) 2010-03-11 2011-09-15 Ucb Pharma, S.A. Pd-1 antibody
TW201134488A (en) * 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
CA2802344C (en) 2010-06-18 2023-06-13 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
DK3323830T3 (en) * 2010-06-19 2023-09-25 Memorial Sloan Kettering Cancer Center ANTI-GD2 ANTIBODIES
US20120014947A1 (en) 2010-07-16 2012-01-19 The University Of Chicago Methods and compositions to reduce liver damage associated with conditions or therapies that affect the immune system
JP5996438B2 (en) 2010-12-22 2016-09-21 国立大学法人 岡山大学 Method for testing chronic inflammatory disease using antibody to inhibitory costimulatory molecule as marker
WO2012113064A1 (en) 2011-02-25 2012-08-30 Bc Cancer Agency Branch Method of diagnosing primary mediastinal b-cell lymphoma or classical hodgkin lymphoma by detecting functional mutation at ciita locus.
EP3398612A1 (en) 2011-03-31 2018-11-07 Merck Sharp & Dohme Corp. Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
HUE037651T2 (en) 2011-04-20 2018-09-28 Medimmune Llc Antibodies and other molecules that bind b7-h1 and pd-1
US9580496B2 (en) * 2011-05-06 2017-02-28 Nexvet Australia Pty Ltd Therapeutic canine immunoglobulins and methods of using same
CA2840170A1 (en) 2011-06-21 2012-12-27 The Johns Hopkins University Focused radiation for augmenting immune-based therapies against neoplasms
PE20190262A1 (en) 2011-08-01 2019-02-25 Genentech Inc METHODS FOR TREATING CANCER BY USE OF PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS
WO2013022091A1 (en) 2011-08-11 2013-02-14 小野薬品工業株式会社 Therapeutic agent for autoimmune diseases comprising pd-1 agonist
CA2849259A1 (en) 2011-09-19 2013-03-28 The Johns Hopkins University Cancer immunotherapy
US8956619B2 (en) 2011-10-25 2015-02-17 University Of Maryland, Baltimore County Soluble CD80 as a therapeutic to reverse immune supression in cancer patients
GB201120527D0 (en) 2011-11-29 2012-01-11 Ucl Business Plc Method
US20150004175A1 (en) 2011-12-13 2015-01-01 Yale University Compositions and Methods for Reducing CTL Exhaustion
WO2013169388A1 (en) 2012-05-08 2013-11-14 H. Lee Moffitt Cancer Center And Research Institute, Inc. Predictive biomarkers for ctla-4 blockade therapy and for pd-1 blockade therapy
WO2013169693A1 (en) 2012-05-09 2013-11-14 Bristol-Myers Squibb Company Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
CN113967253A (en) 2012-05-15 2022-01-25 百时美施贵宝公司 Immunotherapy by disrupting PD-1/PD-L1 signaling
SG11201407859YA (en) 2012-05-31 2014-12-30 Genentech Inc Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
AR091649A1 (en) 2012-07-02 2015-02-18 Bristol Myers Squibb Co OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES
CA2885970C (en) 2012-09-17 2020-10-20 Peter G. Traber Method for enhancing specific immunotherapies in cancer treatment
ES2813340T3 (en) 2012-09-21 2021-03-23 Intensity Therapeutics Inc Cancer treatment method
KR102130865B1 (en) 2012-10-02 2020-08-05 브리스톨-마이어스 스큅 컴퍼니 Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer
CA3201072A1 (en) 2012-10-12 2014-04-17 The Brigham And Women's Hospital, Inc. Enhancement of the immune response
KR101763499B1 (en) * 2012-11-07 2017-07-31 화이자 인코포레이티드 Anti-il-13 receptor alpha 2 antibodies and antibody-drug conjugates
WO2014074852A1 (en) 2012-11-09 2014-05-15 President And Fellows Of Harvard College Compositions and methods for modulating an immune response
US20140147411A1 (en) 2012-11-14 2014-05-29 U.S. GOVERNMENT represented by the UNITED STATES DEPARTMENT OF VETERANS AFFAIRS Methods of treating cancer and testing mutation zygosity related thereto
WO2014100542A1 (en) * 2012-12-21 2014-06-26 Abbvie, Inc. High-throughput antibody humanization
EP2944323B1 (en) 2013-01-11 2019-03-27 Dingfu Biotarget Co., Ltd Agents for treating tumours, use and method thereof
SG10201710472PA (en) 2013-02-22 2018-02-27 Curevac Ag Combination of vaccination and inhibition of the pd-1 pathway
LT2970473T (en) 2013-03-14 2017-10-25 Bristol-Myers Squibb Company Combination of dr5 agonist and anti-pd-1 antagonist and methods of use
MY180687A (en) 2013-03-14 2020-12-07 Icahn School Med Mount Sinai Newcastle disease viruses and uses thereof
JP6586016B2 (en) * 2013-03-15 2019-10-02 ノヴォ ノルディスク アー／エス Antibodies capable of specifically binding to two epitopes on tissue factor coagulation inhibitor
US10544187B2 (en) 2013-03-15 2020-01-28 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
WO2014161509A1 (en) 2013-04-05 2014-10-09 The University Of Hong Kong Novel pd1 isoforms, and uses thereof for potentiating immune responses
EP3003316B1 (en) 2013-05-31 2020-07-22 Merck Sharp & Dohme Corp. Combination therapies for cancer
US9676853B2 (en) 2013-05-31 2017-06-13 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-1
US20160089434A1 (en) 2013-06-03 2016-03-31 Novartis Ag Combinations of an anti-pd-l1 antibody and a mek inhibitor and/or a braf inhibitor
WO2014209804A1 (en) 2013-06-24 2014-12-31 Biomed Valley Discoveries, Inc. Bispecific antibodies
CN104250302B (en) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 The anti-antibody of PD 1 and its application
KR20160037989A (en) 2013-08-02 2016-04-06 아두로 바이오테크 홀딩스, 유럽 비.브이. Combining cd27 agonists and immune checkpoint inhibition for immune stimulation
EP3033415A4 (en) 2013-08-12 2017-01-11 Merck Sharp & Dohme Corp. Methods and compositions for co-expression of polypeptides of interest and il6
AR097306A1 (en) 2013-08-20 2016-03-02 Merck Sharp & Dohme MODULATION OF TUMOR IMMUNITY
AU2013398294A1 (en) 2013-08-22 2016-03-17 The Council Of The Queensland Institute Of Medical Research Immunoreceptor modulation for treating cancer and viral infections
US10966998B2 (en) 2013-09-05 2021-04-06 The Johns Hopkins University Cancer therapy via a combination of epigenetic modulation and immune modulation
WO2015036394A1 (en) 2013-09-10 2015-03-19 Medimmune Limited Antibodies against pd-1 and uses thereof
WO2015038538A1 (en) 2013-09-10 2015-03-19 Medimmune, Llc Compositions and methods for treating sepsis
HUE049281T2 (en) 2013-09-13 2020-09-28 Beigene Switzerland Gmbh Anti-pd1 antibodies and their use as therapeutics and diagnostics
AU2014323523B2 (en) 2013-09-20 2020-02-20 Bristol-Myers Squibb Company Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors
US10350275B2 (en) 2013-09-21 2019-07-16 Advantagene, Inc. Methods of cytotoxic gene therapy to treat tumors
EP3757130A1 (en) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
EP3470081A1 (en) 2013-10-01 2019-04-17 Mayo Foundation for Medical Education and Research Methods for treating cancer in patients with elevated levels of bim
CN104558177B (en) 2013-10-25 2020-02-18 苏州思坦维生物技术股份有限公司 Monoclonal antibody for antagonizing and inhibiting programmed death receptor PD-1and ligand combination thereof, and coding sequence and application thereof
WO2015069697A2 (en) 2013-11-05 2015-05-14 Nkt Therapeutics Inc. Combination therapy
CN105828834A (en) 2013-11-05 2016-08-03 同源生物服务股份有限公司 Combinations of checkpoint inhibitors and therapeutics to treat cancer
RU2714142C2 (en) 2013-11-05 2020-02-12 Бавариан Нордик А/С Combination therapy for treating cancer with poxvirus expressing tumour antigen and antagonist and/or agonist of immune checkpoint inhibitor
EP3074035B1 (en) 2013-11-25 2020-05-13 FameWave Ltd. Compositions comprising anti-ceacam1 and anti-pd antibodies for cancer therapy
WO2015081158A1 (en) 2013-11-26 2015-06-04 Bristol-Myers Squibb Company Method of treating hiv by disrupting pd-1/pd-l1 signaling
WO2015088847A1 (en) 2013-12-11 2015-06-18 Glaxosmithkline Llc Treating cancer with a combination of a pd-1 antagonist and a vegfr inhibitor
SI3081576T1 (en) 2013-12-12 2019-12-31 Shanghai Hengrui Pharmaceutical Co., Ltd., Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
US20160304969A1 (en) 2013-12-17 2016-10-20 Merck Sharp & Dohme Corp. Ifn-gamma gene signature biomarkers of tumor response to pd-1 antagonists
WO2015094996A2 (en) 2013-12-17 2015-06-25 Merck Sharp & Dohme Corp. Pd-l1 gene signature biomarkers of tumor response to pd-1 antagonists
AU2014364601A1 (en) 2013-12-17 2016-07-07 Genentech, Inc. Methods of treating HER2-positive cancers using PD-1 axis binding antagonists and anti-HER2 antibodies
EP3084001A4 (en) 2013-12-17 2017-07-12 Merck Sharp & Dohme Corp. Gene signature biomarkers of tumor response to pd-1 antagonists
WO2015095868A1 (en) 2013-12-20 2015-06-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
WO2015095811A2 (en) 2013-12-20 2015-06-25 The Board Institute Inc. Combination therapy with neoantigen vaccine
US10519251B2 (en) 2013-12-30 2019-12-31 Epimab Biotherapeutics, Inc. Fabs-in-tandem immunoglobulin and uses thereof
US20160340407A1 (en) 2014-01-14 2016-11-24 Dana-Farber Camcer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms
TWI681969B (en) 2014-01-23 2020-01-11 美商再生元醫藥公司 Human antibodies to pd-1
JOP20200094A1 (en) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc Antibody molecules to pd-1 and uses thereof
NZ722891A (en) 2014-02-04 2021-07-30 Incyte Corp Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer
EP3686219A1 (en) 2014-02-04 2020-07-29 Pfizer Inc Combination of a pd-1 antagonist and a 4-1bb agonist for treating cancer
PT3498734T (en) 2014-02-04 2021-12-06 Pfizer Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer
WO2015127158A1 (en) 2014-02-21 2015-08-27 Regeneron Pharmaceuticals, Inc. Methods, compositions and kits for cell specific modulation of target antigens
RS61661B1 (en) 2014-02-21 2021-04-29 Nektar Therapeutics India Pvt Ltd Il-2rbeta-selective agonists in combination with an anti-ctla-4 antibody or an an anti-pd-1 antibody
SG11201607130RA (en) 2014-02-27 2016-09-29 Viralytics Ltd Combination method for treatment of cancer
CN106255510A (en) 2014-03-05 2016-12-21 百时美施贵宝公司 Use the combined therapy renal carcinoma of anti-PD 1 antibody and another anticarcinogen
RU2690670C2 (en) 2014-03-12 2019-06-05 Ида Рисерч Энд Дивелопмент Ко., Лтд Reduced levels or activity of systemic regulatory t cells for treating disease or cns injury
KR20220126813A (en) 2014-03-14 2022-09-16 노파르티스 아게 Antibody molecules to lag-3 and uses thereof
CA2944456C (en) 2014-03-31 2023-10-31 The Johns Hopkins University Use of bacteria, bacterial products, and other immunoregulatory entities in combination with anti-ctla-4 and/or anti-pd-1 antibodies to treat solid tumor malignancies
CN104974253A (en) 2014-04-01 2015-10-14 上海中信国健药业股份有限公司 Anti-CTLA-4/PD-1 bispecific antibody as well as preparation method and application thereof
CN115590953A (en) 2014-05-15 2023-01-13 百时美施贵宝公司（Us） Treatment of lung cancer using a combination of an anti-PD-1 antibody and another anti-cancer agent
CN105085680A (en) 2014-05-23 2015-11-25 复旦大学 Humanized anti-PD-1 and c-MET bispecific antibody, and preparation method and application thereof
CA2949327A1 (en) 2014-05-29 2015-12-03 Medimmune Limited Antagonists of pdl-1 and pd-1 for the treatment of hpv-negative cancers
ES2818800T3 (en) 2014-06-11 2021-04-14 Idac Theranostics Inc Method to reduce the side effects of an immune checkpoint control agent
US20170106067A1 (en) 2014-06-12 2017-04-20 The Johns Hopkins University Combinatorial immunotherapy for pancreatic cancer treatment
US10092645B2 (en) 2014-06-17 2018-10-09 Medimmune Limited Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy
TWI693232B (en) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof
CA2958643A1 (en) 2014-07-07 2016-01-14 Dana Farber Cancer Institute, Inc. Methods of treating cancer
WO2016010879A1 (en) 2014-07-15 2016-01-21 The Johns Hopkins University Suppression of myeloid derived suppressor cells and immune checkpoint blockade
PT3169341T (en) 2014-07-16 2019-09-09 Transgene Sa Oncolytic virus for expression of immune checkpoint modulators
AU2015289533B2 (en) 2014-07-18 2021-04-01 Advaxis, Inc. Combination of a PD-1 antagonist and a Listeria-based vaccine for treating prostate cancer
RU2711141C2 (en) 2014-07-22 2020-01-15 СиБи ТЕРЕПЬЮТИКС, ИНК. Anti-pd-1 antibodies
WO2016014799A1 (en) 2014-07-23 2016-01-28 University Of Iowa Research Foundation Epidermal growth factor and blockade of immune checkpoints in cancer immunotherapy
EP3171896A4 (en) 2014-07-23 2018-03-21 Mayo Foundation for Medical Education and Research Targeting dna-pkcs and b7-h1 to treat cancer
CN105330740B (en) 2014-07-30 2018-08-17 珠海市丽珠单抗生物技术有限公司 Anti- PD-1 antibody and its application
WO2016022813A1 (en) 2014-08-07 2016-02-11 Aerpio Therapeutics, Inc. Combination of immunotherapies with activators of tie-2
HRP20220738T1 (en) 2014-08-11 2022-08-19 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor and/or a pd-l1 inhibitor
WO2016025645A1 (en) 2014-08-12 2016-02-18 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker
DK3180087T3 (en) 2014-08-12 2019-05-13 Alligator Bioscience Ab COMBINATION THERAPIES WITH ANTI CD40 ANTIBODIES
KR20170042778A (en) 2014-08-19 2017-04-19 고꾸리츠 다이가꾸 호우징 오까야마 다이가꾸 Method for enhancing immune cell function and method for assessing immune cell multifunctionality
UA122395C2 (en) 2014-08-19 2020-11-10 Мерк Шарп Енд Доум Корп. ANTIBODY AGAINST TIGIT
JO3663B1 (en) 2014-08-19 2020-08-27 Merck Sharp & Dohme Anti-lag3 antibodies and antigen-binding fragments
US20170247455A1 (en) 2014-08-22 2017-08-31 Bristol-Myers Squibb Company Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody
US10695426B2 (en) 2014-08-25 2020-06-30 Pfizer Inc. Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer
HUE043847T2 (en) 2014-08-28 2019-09-30 Halozyme Inc Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
SG11201701710SA (en) 2014-09-08 2017-04-27 Celgene Corp Methods for treating a disease or disorder using oral formulations of cytidine analogs in combination with an anti-pd1 or anti-pdl1 monoclonal antibody
EP3659621A1 (en) 2014-09-13 2020-06-03 Novartis AG Combination therapies for cancer
WO2016044207A1 (en) 2014-09-15 2016-03-24 The Johns Hopkins University Biomarkers useful for determining response to pd-1 blockade therapy
SG11201701340RA (en) 2014-09-16 2017-03-30 Innate Pharma Neutralization of inhibitory pathways in lymphocytes
IL283834B (en) 2014-09-28 2022-07-01 Univ California Modulation of stimulatory and non-stimulatory myeloid cells
BR112017006664A2 (en) 2014-10-03 2017-12-26 Novartis Ag combination therapies
MA41044A (en) 2014-10-08 2017-08-15 Novartis Ag COMPOSITIONS AND METHODS OF USE FOR INCREASED IMMUNE RESPONSE AND CANCER TREATMENT
ES2753391T3 (en) 2014-10-14 2020-04-08 Halozyme Inc Adenosine deaminase 2 (ADA2) compositions, variants thereof and methods of use thereof
GB201419084D0 (en) 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-PD-1 antibodies
WO2016069727A1 (en) 2014-10-29 2016-05-06 Five Prime Therapeutics, Inc. Combination therapy for cancer
WO2016070001A1 (en) 2014-10-31 2016-05-06 Jounce Therapeutics, Inc. Methods of treating conditions with antibodies that bind b7-h4
PT3212233T (en) 2014-10-31 2020-07-16 Oncomed Pharm Inc Combination therapy for treatment of disease
WO2016073704A1 (en) 2014-11-06 2016-05-12 Children's Research Institute, Children's National Medical Center Immunotherapeutics for cancer and autoimmune diseases
GB2537445A (en) 2014-11-10 2016-10-19 Medimmune Ltd Binding molecules specific for CD73 and uses thereof
EP3218409A2 (en) 2014-11-11 2017-09-20 Sutro Biopharma, Inc. Anti-pd-1 antibodies, compositions comprising anti-pd-1 antibodies and methods of using anti-pd-1 antibodies
WO2016075174A1 (en) 2014-11-11 2016-05-19 Medimmune Limited Therapeutic combinations for treating neoplasia
JP2017537087A (en) 2014-11-13 2017-12-14 ザ ジョンズ ホプキンス ユニバーシティー Checkpoint interruption and microsatellite instability
CN106999583A (en) 2014-11-17 2017-08-01 豪夫迈·罗氏有限公司 Combination treatment comprising OX40 combinations activator and the axle binding antagonists of PD 1
SI3789402T1 (en) 2014-11-20 2022-10-28 F. Hoffmann-La Roche Ag Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists
MA40737A (en) 2014-11-21 2017-07-04 Memorial Sloan Kettering Cancer Center DETERMINANTS OF CANCER RESPONSE TO PD-1 BLOCKED IMMUNOTHERAPY
SG11201703925VA (en) 2014-12-02 2017-06-29 Celgene Corp Combination therapies
JP2017537927A (en) 2014-12-04 2017-12-21 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Combination of anti-CS1 and anti-PD1 antibodies to treat cancer (myeloma)
CN107206088A (en) 2014-12-05 2017-09-26 豪夫迈·罗氏有限公司 It is used for the method and composition for the treatment of cancer using the axle antagonists of PD 1 and HPK1 antagonists
US20170362299A1 (en) 2014-12-08 2017-12-21 1Globe Biomedical Co., Ltd. Soluble Universal ADCC-Enhancing Synthetic Fusion Gene and Peptide Technology and Its Use Thereof
AU2015360903B2 (en) 2014-12-08 2021-03-25 Dana-Farber Cancer Institute, Inc. Methods for upregulating immune responses using combinations of anti-RGMB and anti-PD-1 agents
EP3230498B1 (en) 2014-12-09 2023-01-18 Merck Sharp & Dohme LLC System and methods for deriving gene signature biomarkers of response to pd-1 antagonists
TWI595006B (en) 2014-12-09 2017-08-11 禮納特神經系統科學公司 Anti-pd-1 antibodies and methods of use thereof
MX2017007390A (en) 2014-12-16 2017-11-06 Bristol Myers Squibb Co Use of immune checkpoint inhibitors in central nervous systems neoplasms.
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
ES2881484T3 (en) 2014-12-22 2021-11-29 Pd 1 Acquisition Group Llc Anti-PD-1 antibodies
KR102644115B1 (en) 2014-12-23 2024-03-05 브리스톨-마이어스 스큅 컴퍼니 Antibodies to tigit
SI3240801T1 (en) 2014-12-31 2021-04-30 Checkmate Pharmaceuticals, Inc. Combination tumor immunotherapy
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
GB201500319D0 (en) 2015-01-09 2015-02-25 Agency Science Tech & Res Anti-PD-L1 antibodies
SG10201906471PA (en) 2015-01-14 2019-09-27 Brigham & Womens Hospital Inc Treatment of cancer with anti-lap monoclonal antibodies
EP3244927A1 (en) 2015-01-16 2017-11-22 Vedantra Pharmaceuticals Inc. Multilamellar lipid vesicle compositions including a conjugated anaplastic lymphoma kinase (alk) variant and uses thereof
MA41414A (en) 2015-01-28 2017-12-05 Centre Nat Rech Scient ICOS AGONIST BINDING PROTEINS
CN105983097B (en) 2015-01-28 2021-06-08 华中科技大学同济医学院附属协和医院 Anti-tumor preparation and preparation method thereof
EA201791768A1 (en) 2015-02-06 2018-07-31 КАДМОН КОРПОРЕЙШН, ЭлЭлСи IMMUNODULATING AGENTS
CN104987421A (en) 2015-05-13 2015-10-21 北京比洋生物技术有限公司 Anti-CTLA-4 and PD-1 dual variable domain immunoglobulin
JP6921062B2 (en) * 2015-09-28 2021-08-18 スーヂョウ サンケイディア バイオファーマスーティカルズ カンパニー リミテッド Stable anti-PD-1 antibody pharmaceutical preparation and its application in pharmaceuticals
CN105175545B (en) 2015-10-20 2019-01-25 安徽瀚海博兴生物技术有限公司 A kind of anti-PD-1 bifunctional antibody of anti-vegf-and its application
CN105754990A (en) 2016-01-29 2016-07-13 深圳精准医疗科技有限公司 Preparation method and application of PD-1/CTLA-4 (programmed death-1/cytotoxic T lymphocyte antigen-4) bispecific antibody
TWI764943B (en) * 2016-10-10 2022-05-21 大陸商蘇州盛迪亞生物醫藥有限公司 Combination use of anti-pd-1 antibody and vegfr inhibitor in the preparation of a medicament for the treatment of cancer
CN109806393B (en) * 2017-11-17 2022-07-26 江苏恒瑞医药股份有限公司 Application of anti-PD-1 antibody, pemetrexed and platinum drugs in combined treatment of non-small cell lung cancer
KR102224556B1 (en) * 2018-02-06 2021-03-09 아이-맵 바이오파마 유에스 리미티드 Antibodies against T cell immune receptors (TIGIT) with IG and ITIM domains and their use

Also Published As

Publication number Publication date
CN105026428B (en) 2018-01-16
NZ721624A (en) 2021-10-29
JP6502959B2 (en) 2019-04-17
IL246137B (en) 2020-01-30
WO2015085847A1 (en) 2015-06-18
JP2017500889A (en) 2017-01-12
AU2014361473A1 (en) 2016-07-07
EP3081576A4 (en) 2017-07-05
PH12016501120A1 (en) 2016-08-15
HRP20191678T1 (en) 2019-12-13
CN105026428A (en) 2015-11-04
SI3081576T1 (en) 2019-12-31
EA035037B1 (en) 2020-04-21
US20190309069A1 (en) 2019-10-10
PE20160953A1 (en) 2016-09-26
LT3081576T (en) 2019-10-25
CA2932966A1 (en) 2015-06-18
SG11201604738TA (en) 2016-07-28
DK3081576T3 (en) 2019-10-21
AU2014361473B2 (en) 2019-09-26
MX370449B (en) 2019-12-13
US11365255B2 (en) 2022-06-21
ECSP16060104A (en) 2017-08-31
CY1122245T1 (en) 2020-11-25
MX2016007620A (en) 2017-01-11
EP3081576A1 (en) 2016-10-19
TWI654201B (en) 2019-03-21
IL246137A0 (en) 2016-07-31
CA2932966C (en) 2022-03-22
US20160376367A1 (en) 2016-12-29
CL2016001460A1 (en) 2017-01-20
ME03527B (en) 2020-04-20
BR112016013338A2 (en) 2017-09-26
PT3081576T (en) 2019-10-15
US10344090B2 (en) 2019-07-09
EP3081576B1 (en) 2019-08-21
BR112016013338B1 (en) 2023-11-21
HK1213910A1 (en) 2016-07-15
ZA201604660B (en) 2019-12-18
TW201605901A (en) 2016-02-16
DOP2016000133A (en) 2016-11-30
KR102256152B1 (en) 2021-05-27
PL3081576T3 (en) 2020-03-31
MY184154A (en) 2021-03-23
HUE046249T2 (en) 2020-02-28
KR20160113113A (en) 2016-09-28
EA201691225A1 (en) 2016-09-30
CR20160319A (en) 2016-11-08
PH12016501120B1 (en) 2016-08-15
ES2746805T3 (en) 2020-03-06
RS59480B1 (en) 2019-12-31
UA119659C2 (en) 2019-07-25

Similar Documents

Publication Publication Date Title
SG10201804945WA (en) Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
MX2018015393A (en) Lag-3 antibody, antigen-binding fragment thereof, and pharmaceutical application thereof.
PH12016502345A1 (en) Anti-gitr antibodies and methods of use thereof
ZA202004701B (en) Anti-b7-h4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof
MX2019011117A (en) B7-h3 antibody, antigen-binding fragment thereof and medical use thereof.
MX2021011489A (en) Anti-claudin 18.2 antibody and application thereof.
PH12018550179A1 (en) Anti-pd-1 antibodies, method for producing same and method for using same
MX2020004503A (en) Humanized or chimeric cd3 antibodies.
MX2020007406A (en) Pd-l1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof.
MX2021005396A (en) Anti-cd73 antibody, antigen-binding fragment thereof and application thereof.
MX2019014375A (en) Anti-cd40 antibody, antigen binding fragment thereof and medical use thereof.
NZ626242A (en) Anti-asic1 antibodies and uses thereof
MX2021001143A (en) Human il-4r binding antibody, antigen binding fragment thereof, and medical use thereof.
MX2021009041A (en) Anti-pd-1 antibody, antigen-binding fragment thereof and pharmaceutical use thereof.
MX2018009264A (en) Thrombin antibody, antigen-binding fragment and pharmaceutical use thereof.
MX2020008730A (en) B7-h4 antibody dosing regimens.
MX2020010119A (en) Anti-cd27 antibody, antigen-binding fragment thereof and medical use thereof.
MX2021002531A (en) Anti-cd38 antibody, antigen-binding fragment thereof, and pharmaceutical use.
MX2019009498A (en) Fgf21 mimetic antibodies and uses thereof.
MX2019015914A (en) Chimeric antibodies for treatment of amyloid deposition diseases.
MX2015002465A (en) Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor 1 (igf-1).
MX2018007925A (en) Pcsk9 antibody, antigen-binding fragment thereof, and medicinal application thereof.
MX2017011480A (en) Anti-sclerostin antibody, antigen binding fragment and medical use thereof.
MX2023004314A (en) Therapeutic anti-cd40 ligand antibodies.
MX2020002750A (en) Il-6r antibody and antigen binding fragment thereof and medical use.